title: Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia.
abstract: Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are highly prevalent in older men. Medical therapy is the first-line treatment for LUTS associated with BPH. Mainstays in the treatment of male LUTS and clinical BPH are the α(1)-adrenergic receptor antagonists. Silodosin is a new α(1)-adrenergic receptor antagonist that is selective for the α(1A)-adrenergic receptor. By antagonizing α(1A)-adrenergic receptors in the prostate and urethra, silodosin causes smooth muscle relaxation in the lower urinary tract. Since silodosin has greater affinity for the α(1A)-adrenergic receptor than for the α(1B)-adrenergic receptor, it minimizes the propensity for blood pressure-related adverse effects caused by α(1B)-adrenergic receptor blockade. In the clinical studies, patients receiving silodosin at a total daily dose of 8 mg exhibited significant improvements in the International Prostate Symptom Score and maximum urinary flow rate compared with those receiving placebo. Silodosin showed early onset of efficacy for both voiding and storage symptoms. Furthermore, long-term safety of silodosin was also demonstrated. Retrograde or abnormal ejaculation was the most commonly reported adverse effect. The incidence of orthostatic hypotension was low. In conclusion, silodosin, a novel selective α(1A)-adrenergic receptor antagonist, was effective in general and without obtrusive side effects. This review provides clear evidence in support of the clinical usefulness of silodosin in the treatment of LUTS associated with BPH.
authors.affiliation: Department of Medical Informatics, University of Tokyo, Japan. akko-maki@umin.net
authors.forename: Masaki
authors.initials: M
authors.lastname: Yoshida
authors.forename: Junzo
authors.initials: J
authors.lastname: Kudoh
authors.forename: Yukio
authors.initials: Y
authors.lastname: Homma
authors.forename: Kazuki
authors.initials: K
authors.lastname: Kawabe
mesh_terms: D018674:Adrenergic Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000368:Aged; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic
chemical_list: D018674:Adrenergic Antagonists; D007211:Indoles; C095285:silodosin